Patients diagnosed with pancreatic cancer wish to live longer, better lives, with hope for cure. Radiotherapy can effectively palliate symptoms, but its association with prolonged survival remains controversial. Fortunately, improvements in survival have occurred over recent decades, mostly owing to advances in cytotoxic chemotherapy. Intensified multiagent chemotherapy, first trialed in the metastatic setting, is now frequently used in patients with resectable pancreatic ductal adenocarcinoma (PDAC), underscoring the notion that even in early stages, PDAC represents a systemic disease. In this setting, can any additional local control afforded by radiation therapy translate to a survival advantage when added to surgery and chemotherapy?
Sanford NN, Yeap BY, Hong TS. Measuring the Effect of Local Control From Radiotherapy in Patients With Pancreatic Adenocarcinoma. JAMA Oncol. 2022;8(3):337–338. doi:10.1001/jamaoncol.2021.7037
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.